lactoferrin and Hyperglycemia

Obesity, dyslipidemia, hyperglycemia/type II diabetes and hypertension together constitute the so-called metabolic syndrome. Frequency of occurrence of these serious metabolic disturbances is associated with life style and is on the rise in prosperous industrialized countries. These diseases represent not only a serious health problem but also social and economic ones, and involve in prophylaxis and treatment various specialists (physicians, dieticians and psychologists). For about two decades research has been conducted on the possibility to apply milk-derived proteins in prevention and treatment of the above mentioned metabolic diseases. Lactoferrin (LF), a protein present in milk and excretory fluids of mammals, is one of the most intensively studied milk proteins for therapeutic application. Initial trials revealing an advantageous effect of LF on lipid metabolism and obesity enrolled only a few volunteers and were performed in Japan in 2003. Subsequent trials were conducted on animals as well as in clinics, and the positive results were supported by in vitro tests. After oral administration of LF, decreases of body weight, waist measurement, visceral fat tissue, plasma and liver fatty acid concentrations, triglycerides and cholesterol were registered. The mechanism of LF action may involve several processes, such as inhibition of adipogenesis, decrease of dietary triglyceride absorption, elevation of HDL cholesterol possessing anti-atherogenic properties, inhibition of accumulation of oxidized LDL cholesterol forms in macrophages and protection against formation of foam cells. LF also increases the susceptibility of cells to insulin action, including in conditions when the response to insulin is lowered (during inflammation). In addition, LF regulates activity of insulin-like growth factor (IGF). The data collected to date indicate that LF is a promising, completely nontoxic, natural remedy which (as for example a food supplement) may be applied in long-term prophylaxis and therapy of metabolic disturbances, such as dyslipidemia, obesity and insulin resistance/type II diabetes. 

Topics: Animals; Blood Glucose; Cholesterol, HDL; Humans; Hyperglycemia; Insulin Resistance; Japan; Lactoferrin; Lipid Metabolism; Metabolic Syndrome; Obesity; Somatomedins; Triglycerides

Although the relationship between type 2 diabetes (T2D) and the increased risk of colorectal carcinogenesis is widely defined in clinical studies, the therapeutic methods and molecular mechanism of T2D-induced colon cancer and how does hyperglycemia affect the progression is still unknown. Here, we studied the function of lactoferrin (LF) in suppressing the progression of colon cancer in T2D mice, and uncovered the related molecular mechanisms in DNA 5mC and RNA m6A levels.. A special gene NT5DC3 was screened out through co-analysis of transcriptomics and DNA methylation profiling, and HKDC1 might be a downstream sensor of NT5DC3. Mechanistically, LF-dependent cellular DNA 5mC and RNA m. Together, this study reveals that lactoferrin acts as a major factor to repress the progression of colon cancer under hyperglycemia, thus, significantly expanding the landscape of natural dietary mediated tumor suppression.

Topics: Animals; Cell Cycle Proteins; Colonic Neoplasms; Diabetes Mellitus, Type 2; Disease Models, Animal; Hexokinase; Humans; Hyperglycemia; Lactoferrin; Mice; RNA Splicing Factors

We aimed to assess the effects of lactoferrin (Lf) on glycemic regulatory responses under restraint stress (RS) in rats. Bovine Lf (bLf, 100 mg/kg) was intraperitoneally administered to rats before oral saline administration or oral glucose tolerance test (OGTT) following 60 min of RS load. In the case of oral saline administration, RS significantly raised plasma glucose, but bLf did not affect the level. Plasma glucose in OGTT showed an overall lower transition in the bLf group, and the levels at 30 and 180 min or the area under the curve (AUC) were significantly decreased. Although bLf suppressed an increase in plasma corticosterone during RS, the levels of plasma insulin, epinephrine and glucagon were not changed by the bLf treatment.

Topics: Animals; Blood Glucose; Corticosterone; Glucose Tolerance Test; Hyperglycemia; Lactoferrin; Male; Rats; Rats, Wistar; Restraint, Physical; Stress, Physiological